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Abstract
Background: The risk/benefit ratio of using statins for primary prevention of cardiovascular (CV) events in elderly
people has not been established. The main objectives of the present study are to assess the cost-effectiveness of
statin cessation and to examine the non-inferiority of statin cessation in terms of mortality in patients aged 75 years
and over, treated with statins for primary prevention of CV events.
Methods: The “Statins in the elderly” (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-
centre, randomized clinical trial that is being conducted in two parallel groups in outpatient primary care offices.
Participants meeting the following criteria are included: people aged 75 years and older being treated with statins
as primary prevention for CV events, who provide informed consent. After randomization, patients in the statin-
cessation strategy are instructed to withdraw their treatment. In the comparison strategy, patients continue their
statin treatment at the usual dosage. The cost-effectiveness of the statin-cessation strategy compared to continuing
statins will be estimated through the incremental cost per quality-adjusted life years (QALYs) gained at 36 months,
from the perspective of the French healthcare system. Overall mortality will be the primary clinical endpoint. We
assumed that the mortality rate at 3 years will be 15%. The sample size was computed to achieve 90% power in
showing the non-inferiority of statin cessation, assuming a non-inferiority margin of 5% of the between-group
difference in overall mortality. In total, the SITE study will include 2430 individuals.
Discussion: There is some debate on the value of statins in people over 75 years old, especially for primary
prevention of CV events, due to a lack of evidence of their efficacy in this population, potential compliance-related
events, drug-drug interactions and side effects that could impair quality of life. Data from clinical trials guide the
initiation of medication therapy for primary or secondary prevention of CV disease but do not define the timing,
safety, or risks of discontinuing the agents. The SITE study is one of the first to examine whether treatment
cessation is a cost-effective and a safe strategy in people of 75 years and over, formerly treated with statins.
Trial registration: ClinicalTrials.gov: NCT02547883. Registered on 11 September 2015.
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Background
Cardiovascular (CV) events, including ischaemic heart
disease and cerebrovascular diseases, are the leading
cause of death worldwide and are a major cause of mor-
bidity in industrialised and developing countries [1]. CV
events are multifactorial, and their prevention is defined
as a coordinated set of actions, at the population or indi-
vidual level, intended to eliminate or minimise the im-
pact of CV diseases and related disabilities.
According to the “2016 European Guidelines on Cardio-
vascular Disease Prevention in Clinical Practice”, total CV
risk estimation based on a risk estimation system such as
the Systematic Coronary Risk Evaluation (SCORE), which
estimates the 10-year risk of fatal cardiovascular disease
(CVD), is recommended for adults > 40 years old [2]. People
are categorised as being at high risk (familial hypercholester-
olaemia, blood pressure > 180/110, diabetes mellitus without
organ damage, or moderate chronic kidney disease (CKD);
glomerular filtration rate (GFR) 30–59 mL/min/1.73 m2)”
and “calculated SCORE between 5% and 10%) or very high
risk (documented CV disease, diabetes mellitus with target
organ damage, severe CKD (GFR < 30 mL/min/1.73 m2),
calculated SCORE ≥ 10%) for CV events”.
The 2019 American College of Cardiology (ACC) and
American Heart Association (AHA) Guidelines on the
Primary Prevention of Cardiovascular Disease also rec-
ommend that adults aged 40–75 years who are being
evaluated for CV disease prevention undergo 10-year es-
timation of risk of atherosclerotic CVD [3].
Among the possible interventions to reduce CV risk,
statins are recommended for secondary prevention in all
patients with CVD and for primary prevention in pa-
tients with elevated low-density lipoprotein cholesterol
(≥ 190 mg/dL) or with diabetes mellitus, and those deter-
mined to be at sufficient CV risk (high risk and very
high risk) after a clinician–patient discussion of risk.
Statins are inhibitors of hydroxymethylglutaryl-CoA
reductase and thus reduce the synthesis of cholesterol, es-
pecially low-density lipoprotein (LDL) cholesterol, an inde-
pendent risk factor for CV events. Numerous large-scale
randomized studies over the last 20 years have demon-
strated the effectiveness of statins for reducing CV risk in
primary and secondary prevention [4]. However, informa-
tion on patients over 75 years old is lacking, as no random-
ized trials have been conducted in this population.
The European Guidelines and the 2019 ACC/AHA
Guideline acknowledge that special considerations are
required when prescribing lipid-lowering agents in older
people because exposure to higher doses (or higher po-
tency) may not increase life expectancy but may increase
the risk of adverse effects. Assessment of risk status
and a clinician–patient discussion of risk are needed
to decide whether to initiate or continue statin
treatment.
Statins represent one of the largest pharmaceutical in-
dustry markets in France; in 2014, around 5 million people
were treated with statins, representing a total cost of 550
million euros. People 75 years and older represented 9.3%
of the total population in 2019 [5]. We estimate that
around 25% of these people are treated with statins, in-
cluding around 40% in the context of primary prevention
(target population over 500,000 people in France).
Given the absence of formal evidence of efficacy, and the
high level of side effects, the risk/benefit ratio of primary
prevention with statins in elderly patients has not been
established. With no controlled studies to validate the bene-
fits of statins in this population, there is some controversy
in the literature about their use in this age group [6–16].
One previous trial implied that stopping statin medica-
tion therapy is safe and may be associated with a num-
ber of benefits, including improved quality of life (QOL)
among patients with advanced life-limiting illness [17].
We postulate that statin cessation in patients older
than 75 years, when prescribed for primary prevention of
CV events, will be safe and may improve QOL through
the absence of adverse effects, and lower the costs for
the French National Health Insurance System.
The two main objectives of this study are therefore to as-
sess the cost-effectiveness, in real-life use, of statin cessation
in patients over 75 years old being treated for primary pre-
vention of CV events and to examine the non-inferiority of
statin cessation in terms of all-cause mortality in patients
older than 75 years.
Methods/design
Trial design and settings
The Statins in the elderly (SITE) study is a 3-year follow-
up, open-label, comparative multi-centre randomized clin-
ical trial being conducted in two parallel groups in out-
patient primary care offices. Our objective is to conduct a
randomized controlled trial that is representative of usual
care conditions. Our study is being conducted in general
practices in France, and the eligibility criteria are limited,
apart from regulatory requirements, to age and treatment
with statins for the purpose of primary prevention.
All general practitioners (GPs) working in primary
care centres in France can enrol patients in the study.
They need only to use informatics devices to complete
the electronic case report forms (e-CRF) during patient
follow up.
Eligibility criteria
The study population consists of patients aged 75 years
and over who have no history of CV disease and who
are being treated with a statin and regularly visiting their
referent GP in France. Participants meeting the follow-
ing criteria are eligible for inclusion: people aged 75
years and older who have been treated with statins for at
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least 1 year for primary prevention of CV events, and
who give informed consent. Patients with hypertension
and/or diabetes mellitus may be included.
Participants meeting any of the following criteria are
excluded: progressive morbid disease and life expectancy
of 3 months or less, diagnosed with dementia, suffering
from known homozygous or double heterozygous famil-
ial hypercholesterolaemia, or unable to provide informed
consent.
Intervention
In the statin cessation strategy, the statins are stopped
and patients are asked to end their treatment on the day
of randomization. In the comparison strategy, patients
continue their statin treatment at the usual dosage.
Compliance with the use of statins is assessed by the
Morisky questionnaire at each visit.
Randomization
Randomization is being carried out centrally using the e-
CRF on the day of the visit for participant inclusion, after
the participant has signed the consent form. Participants
are considered enrolled in the trial when randomized.
The randomization is unbalanced, with a 5:4 ratio in
favour of the statin-continuation group to take into ac-
count a 20% risk that patients allocated to the statin con-
tinuation group will stop statins after randomization for
any reason (side effects, patient’s decision, physician’s de-
cision). The allocation sequence was elaborated using
computer-generated random numbers, and was not strati-
fied. To reduce predictability of a random sequence, we
used blocks of varying size. A document describing the
randomization procedure is kept confidential within the
Clinical Epidemiology Unit.
Taking statins or discontinuing statins will not require
alteration to usual care pathways (including use of any
medication) and these will continue in both trial arms.
Participants in the statin discontinuation group who ex-
perience a new vascular event will be allowed to restart
statins at the discretion of the investigator and according
to good clinical practice.
Outcome measures
Economic endpoints
The cost-effectiveness of the statin cessation strategy
compared to continuation of statins will be estimated
based on the incremental cost per quality-adjusted life
year (QALY) gained at 36 months, from the perspective
of the French healthcare system. QALYs will be mea-
sured using the Euro-QOL five-dimension, three-level
(EQ-5D-3 L) questionnaire at inclusion and at each
follow-up visit [18]. This questionnaire has been vali-
dated in the French population.
Healthcare resources and costs will be extracted from
the French Administrative Health Care Database (Système
National des Données de Santé, SNDS) by a merging pro-
cedure, operated by the French National Health Insurance
Fund and using data from the SITE trial. The SNDS
gathers all reimbursement data for 98.8% of the French
population [19]. The time horizon of the study (36
months) implies a discounting of costs and outcomes. In
accordance with the methodological economic guidelines
of the French National Health Authority (Haute Autorité
de Santé, HAS), we will apply a 4% discount rate.
Following cost-effectiveness analysis (CEA), budget
impact analysis (BIA) will provide useful information
about the sustainability of the statin cessation strategy if
it were applied to the entire French healthcare system. It
will consider outpatient costs, hospital costs, medical
and non-medical costs induced or avoided by stopping
statins, and all budgetary implications related to changes
in health management and/or health status improve-
ment. The difference between induced and avoided costs
will provide the net benefit to the healthcare system of
widespread adoption of the statin cessation strategy for
primary prevention among elderly individuals in France.
Main clinical endpoint
Overall mortality will be the primary clinical endpoint.
As the investigators are GPs, they are informed of the
death of their patients and will therefore constitute the
source of mortality data in this trial.
Secondary endpoints
The secondary endpoints are:
– QOL score measured by the Quality of Life Scale
SF12, which has been validated in older people
– Incidence of CV events
– Incidence of non-CV events (diabetes mellitus and
cognitive disorders)
Timeline and recruitment
This study employs the research network of French univer-
sities’ primary care departments (PCDs). Each PCD appoints
a coordinating physician by geographic area to mobilise in-
vestigating physicians (486 expected in the study).
The recruitment of GPs all across France maximises
representativeness and limits the impact of potential
local practices. The representativeness of the investiga-
tors is being documented by collecting data about their
sociodemographic profiles, activity, and training.
Patients are being recruited through consultations over
a period of 36 months. Eligible patients not included in
the study are being reported, along with the reason for
non-inclusion.
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Conduct of research
Patients are approached and screened by GPs during
their usual medical visit or on the renewal of their medi-
cation. Patients are first pre-included with their referent
GP, and then after a time of reflection (that may be few
minutes to days or months until the next visit), they sign
the consent form with the GP and are randomized to
one of the two strategies. On the consent form, partici-
pants are asked if they agree to use of their data should
they choose to withdraw from the trial. Participants are
also asked for permission for the research team to share
relevant data with people from the Universities taking
part in the research or from regulatory authorities,
where relevant. This trial does not involve collecting bio-
logical specimens for storage. Table 1 outlines the differ-
ent phases of the study and data collection.
Sample size
According to data from the French National Institute for
Statistics and Economic Studies (Institut National de la Sta-
tistique et des Études Économiques, INSEE) in the French
population aged 75 years or older, we assume that mortality
at 3 years in both study groups will be 15%.
The SITE sample size was computed to achieve 90%
power in showing the non-inferiority of statin cessation in
comparison to statin continuation, assuming a 2.5% unilat-
eral α risk and a non-inferiority margin of 5% of the
between-group difference in overall mortality at 3 years
after randomization (nQuery Advisor software, v. 7.0). A
5% non-inferiority margin is fairly commonly reported in
the literature, but 3-year follow up is not. This yields an
annual non-inferiority margin of only 1.7%, which we think
would be quite acceptable for the scientific community. We
do not have to deal with multiple tests, as cost-effectiveness
analyses do not require statistical testing [20].
We also assume that 20% of the individuals random-
ized to the statin-continuation group may spontaneously
stop their treatment during follow up. Therefore, to en-
sure 90% statistical power in under-treatment analysis, it
was decided to include 20% more individuals in the sta-
tin continuation group. In total, 2430 individuals will be
enrolled in the SITE study, including 1080 in the statin

















Standardised questionnairea ✓ ✓ ✓ ✓ ✓
MMSEb ✓ ✓
Consent signature ✓
Intervention ✓ ✓ ✓ ✓ ✓
Assessment
SF12 and EQ-5D-3 L Questionnairesc ✓ ✓ ✓ ✓ ✓
Clinical examinationd ✓ ✓ ✓ ✓ ✓ ✓
Biological testse ✓(*) ✓ ✓ ✓ ✓
ECGf ✓ ✓ ✓ ✓
Clinical event data collectiong ✓ ✓ ✓ ✓ ✓
Complianceh ✓ ✓ ✓ ✓ ✓
CVRF collectioni ✓ ✓ ✓ ✓ ✓
SE/SAE collection j ✓ ✓ ✓ ✓ ✓
aStandardised questionnaire with six questions to search for coronary disease history, stroke, or unnoticed peripheral artery disease
bMini-Mental State Examination (French version, GRECO)
cQuality of Life Questionnaire SF12 (self-administered) and EQ-5D 3 L (self-administered)
dClinical examination: examination as recommended by good clinical practices in the field of cardiovascular medicine (blood pressure, cardiovascular (CV) data,
and lung auscultation)
eLaboratory tests: lipid (EAL), blood glucose, HbA1c (if diabetic), electrolytes, creatinine, creatinine clearance, and serum albumin. *In the absence of a balance
sheet dated within 12months before pre-inclusion, laboratory tests are prescribed at pre-inclusion and should be performed until the day of the inclusion visit
fECG: electrocardiogram based on recommendations (once every 3 years if permanent arterial hypertension (HTA) and once a year if overt diabetes mellitus)
gReports of significant clinical events occurring between visits
hCompliance assessed by Morisky questionnaire (eight items) at baseline (all patients) and during follow up (only in the group of patients in whom statin therapy
is continued)
iTotal CV risk factors: weight, waist circumference, smoking, hypertension, diabetes mellitus, previous family history of CV disease among first-degree relatives,
high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol
jSE/SAE: side effects and serious adverse events, respectively
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cessation group and 1350 in the statin continuation
group.
Data management
The e-CRF is the primary data collection instrument for
the study. Medical information for individual partici-
pants obtained as a result of this study is considered
confidential, and disclosure to third parties is prohibited.
The e-CRFs are labelled with a unique trial number.
Consent forms sent to Sponsors may contain patient
identifiers for the purpose of monitoring, as described in
the trial risk assessment. Such information will be stored
in secure, locked storage. Monitoring is mainly per-
formed through e-CRF and by telephone. However, on-
site monitoring is performed after the 3-month follow
up and after the last follow up in each of the recruitment
sites. Auditing may be required by the Sponsor or by the
French authorities (ANSM) and the process is independ-
ent from investigators and the Sponsor.
Statistical methodology
In the non-inferiority analysis, the bilateral 95% confi-
dence interval (CI) for the between-group difference in
the 3-year mortality rate will be estimated. Considering <
5% change as clinically non-significant, we will consider
non-inferiority demonstrated only if the 95% CI upper
bound of the 3-year mortality difference between the two
groups is < 5%. This analysis will primarily be performed
according to an under-treatment principle. Formally,
patients who do not receive the trial treatment as planned
in the protocol will be excluded from the analysis. An
intention-to-treat analysis will also be performed with the
aim of maintaining the initial effect of randomization. The
“missing = failure” strategy (failure being defined as death)
will be used in the non-inferiority analysis.
Secondary clinical analyses will be conducted accord-
ing to the intention-to-treat principle: all randomized
patients will be analysed in the group to which they were
initially randomized, and all of their data will be used re-
gardless of eventual treatment changes during the study.
As economic analysis is not based on statistical tests, no
adjustment of the α-level is needed to deal with multiple
comparisons. In all analyses, p < 0.05 will be taken to in-
dicate statistical significance. A statistical team will ana-
lyse all data independently of the investigator.
The economic analysis will also be conducted according
to the intention-to-treat principle. First, the point estimate
of the incremental cost/utility ratio and its bootstrap 95%
CI will be calculated. We will then estimate the incremen-
tal net monetary benefit (INMB) adjusted for potential
confounding factors (adherence to statins at baseline,
treatment duration, and particular statin dosage) using
multiple linear regression models. Acceptability curves
will then be plotted. The value of information will also be
examined according to the principles proposed by Claxton
[20].
Safety and adverse event reporting
The adverse events expected during this research are
mainly those related to the age of the study population,
such as CV events, diabetes mellitus and/or its complica-
tions, cognitive disorders and dementia, falls, cancers,
deaths, and adverse effects of concomitant therapies.
Given that one group of patients will continue to use
statins, adverse reactions listed in the summaries of
product characteristics are also expected.
The Sponsor unit charged with security and vigilance
must be informed immediately of any serious adverse
events (SAEs), regardless of whether expected or unex-
pected, via the eCRF. This ensures continuous monitor-
ing of safety of patients included throughout the trial.
Moreover, annual safety evaluations will be conducted
by the security and vigilance unit of the Sponsor, with
particular focus on CV morbidity and all-cause mortality
in both groups. The Data Safety Monitoring Board
(DSMB) of the study will meet when 50% of the patients
reach 12 and 24 months of follow up. We did not antici-
pate criteria by which the trial may be stopped, but the
advice of the DSMB could be solicited in the case of un-
expected safety issues or new information. In addition,
all CV events will be validated by an external adjudica-
tion committee, which includes a cardiologist, a neurolo-
gist, and an internal and a geriatric medical specialist.
The Sponsor’s security and vigilance unit must com-
municate serious unexpected adverse reactions (SUSA
Rs) and new information in the research in a timely
manner in accordance with current regulations:
– To the French National Agency for the Safety of
Medicines and Health Products, (Agence Nationale
de Sécurité du Médicament et des Produits de Santé
(ANSM)).
– To the research ethics committee (Comité de
Protection des Personnes (CPP)). The committee
will ensure, if necessary, that the research
participants were informed about the side effects
and confirm their consent.
On the anniversary date of first inclusion, the security
and vigilance unit prepares an annual safety report
including:
– A list of serious side effects of the research
– A concise and critical analysis of the safety of
participants in the research
This report is sent to the ANSM and the CPP within
60 days of the anniversary date of first inclusion.
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Trial management
The scientific committee (SC) is composed of the coordinat-
ing investigator, Sponsor representatives, pharmacist, statisti-
cian, general practitioner, cardiologist, and geriatrics and
experts in the field. The frequency of the SC meeting is at
least once a year as needed during the research. The SC pro-
vides overall supervision of the trial; it will ensure that the
study is carried out appropriately, scientifically, clinically and
ethically. The SC is the decision-making executive body for
all issues related to the trial implementation or follow up.
The DSMB is composed of six experienced external ex-
perts in the field of general practice, cardiology, geriatric
medicine, methodology, and pharmacy, and are all nomi-
nated by the trial Sponsor. The DSMB is a consultative
board for the SC and the Sponsor. It monitors the main
safety and efficacy outcome measures and the overall con-
duct of the trial, with the aim of protecting the participants’
safety and interests. The DSMB will meet when 50% of the
participants reach 12 and 24months of follow up.
The day to day activities are supervised by a project
coordination team that meets every 3 months and refers
to the SC. The events validation committees will be in
charge of validating neurovascular and cardiovascular
events that occur during the course of the trial. This
committee will meet to validate clinical events before
the DSMB meeting to ensure that the results provided
to the DSMB are consolidated.
Trial registration
This research has been registered with ClinicalTrials.gov
under the number NCT02547883.
Amendment
To extend inclusions, the protocol was amended in March
2019 to also include patients from hospital departments.
Discussion
The proportion of the population represented by people
aged 75 years and older is increasing at a rapid rate in
industrialised countries. According to the French National
Institute of Demographic Studies (Institut National
d’Études Démographiques, INED), life expectancy at age
75 years in France is 11.5 years in men and 14.4 years in
women. Statins are among the most widely prescribed
pharmacological treatments in this population.
Data from clinical trials guide the initiation of medica-
tion therapy for primary or secondary prevention of CV
disease but do not clearly define the timing, safety, or
risks of discontinuing treatment with these agents. As a
result, the number of medications often accumulates,
particularly in elderly people, with increased risk of
drug–drug interactions and side effects.
There is debate on the value of statins in people aged 75
years and older, especially for primary prevention of CV
events, particularly due to the lack of evidence of their effi-
cacy in this population, potential compliance-related events,
drug–drug interactions, and side effects that could impair
the QOL of patients in this age group who are treated with
statins [21–29]. In addition, the health economics literature
does not demonstrate the cost-effectiveness of statin ther-
apy for primary prevention in this population [30, 31].
To date, the SITE study is one of the largest studies con-
ducted in France in the primary care setting among GPs,
who are usually poorly trained with regard to randomized
clinical trials. Therefore, to perform such a study, we have
implemented a specific online questionnaire, which is as
short as possible and includes only the key variables, to limit
the problem of missing data, and have provided specific on-
line courses to train the GP investigators in good clinical
practices in the field of clinical research. We have also rein-
forced the data monitoring through our web system, the e-
CRF, and phone calls made by experienced and trained re-
search assistant. Also, we perform a systematic on-site mon-
itoring visit after 3months of follow up and after the last
follow up at each of GP site. Finally, GPs are paid for their
time spent on the trial (i.e. 50 euros per visit corresponding
to two consultations).
Our study will have some limitations. First, we acknow-
ledge that this is a pragmatic trial without blinding. The
study participants and their physicians will know whether
statin therapy has been continued or discontinued. The
choice was to evaluate a strategy of discontinuing statins ra-
ther than to evaluate statin prescriptions alone. In theory,
the absence of blinding could lead to a measurement bias
due to greater surveillance of CV events in the discontinu-
ation group. This will be closely monitored through the data
from the SNDS. In addition, this is why the total mortality
rate was chosen as our primary endpoint. Second, patients
with previous dementia cannot be included in the trial, so
our results will not be generalizable to this population.
Third, although our sample is quite large, we cannot exclude
a tendency from the investigators to recruit people with very
few CV risk factors rather than patients with advanced dis-
ease and poor outcomes. Particularly, the inclusion of pa-
tients with diabetes mellitus will be monitored. Finally,
patients treated with statins are being included in the SITE
trial regardless of the specific type of statin. Therefore, we
will not be able to examine specific treatments or dosages.
However, we believe that the SITE study will be one of the
first to show that a strategy of treatment cessation is cost-
effective and does not adversely affect the prognosis of
people over 75 years of age who are treated with statins.
Trial status
Patient recruitment started on 15 June 2016. The ex-
pected recruitment completion date is 31 December
2019.
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The protocol version number is 8.0, dated 5 June
2019.
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